4//SEC Filing
ROBERTS EIRY 4
Accession 0000914475-25-000069
CIK 0000914475other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 6:42 PM ET
Size
25.5 KB
Accession
0000914475-25-000069
Insider Transaction Report
Form 4
ROBERTS EIRY
Chief Medical Officer
Transactions
- Sale
Common Stock
2025-02-13$116.90/sh−1,114$130,232→ 34,252 total - Exercise/Conversion
Common Stock
2025-02-13+1,372→ 36,140 total - Award
Stock Option
2025-02-12+43,261→ 43,261 totalExercise: $117.18Exp: 2035-02-12→ Common Stock (43,261 underlying) - Sale
Common Stock
2025-02-13$116.74/sh−604$70,510→ 34,768 total - Award
Restricted Stock Unit
2025-02-12+8,108→ 8,108 total→ Common Stock (8,108 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-02-13−1,372→ 4,115 total→ Common Stock (1,372 underlying) - Exercise/Conversion
Common Stock
2025-02-13+2,113→ 35,366 total - Sale
Common Stock
2025-02-14$115.04/sh−500$57,521→ 35,640 total - Exercise/Conversion
Restricted Stock Unit
2025-02-13−2,113→ 4,227 total→ Common Stock (2,113 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-02-13−1,120→ 3,363 total→ Common Stock (1,120 underlying) - Exercise/Conversion
Common Stock
2025-02-13+1,120→ 35,372 total
Footnotes (12)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F10]This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, and will vest as to 2,113 shares on February 13, 2026, and 2,114 shares on February 13, 2027, subject to the terms and conditions of the award.
- [F11]This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, and will vest as to 1,121 shares on February 13, 2026, 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award.
- [F12]This RSU was granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, and will vest as to 1,372 shares on February 13, 2026, 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.24 to $117.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F4]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $118.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $114.76 to $115.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F6]34,455 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
- [F7]Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- [F8]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- [F9]The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001727606
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 6:42 PM ET
- Size
- 25.5 KB